Effect of CD80 and CD86 blockade and anti‐interleukin‐12 treatment on mouse acute graftversus‐host disease

We investigated the efficacy of a combination of anti‐CD80 and CD86 (CD80 + 86) monoclonal antibodies (mAb), anti‐interleukin (IL)‐12 mAb, or both, for prophylaxis in a mouse acute graft‐versus‐host‐disease (GVHD) model. The treatment with a combination of anti‐CD80 + 86 mAb efficiently reduced the lethality of GVHD, whereas mAb against either CD80 or CD86 alone had an effect. A delay in lymphocyte reconstitution and GVHD‐associated histological changes in organs was observed at 30 days post‐bone marrow transplantation (BMT) even in the anti‐CD80 + 86 mAb‐treated mice, although these manifestations were resolved by 100 days. In vitro, host alloantigen‐specific T cell proliferative responses and generation of CTL were significantly reduced by anti‐CD80 + 86 treatment. Furthermore, anti‐CD80 + 86 mAb preferentially inhibited the production of interferon (IFN)‐γ, but not IL‐4 and IL‐10, when cultures were assayed at 21 days. Although the anti‐IL‐12 mAb treatment alone inhibited the generation of cytotoxic T lymphocytes and IFN‐γ production in vitro, administration of anti‐IL‐12 mAb in vivo reversed the beneficial effects of anti‐CD80 + 86 treatment on host survival post‐BMT. The adverse effect of anti‐IL‐12 treatment seems to result from impairment of natural immunity and hematopoiesis, rather than as a consequence of an incomplete blockade of T helper (Th)1 responses. Our results suggest that the prevention of GVHD‐induced death results from the efficient blockade of Th1 cell activation by the anti‐CD80 + 86 treatment. However, further treatment is required for a complete prevention of GVHD, which seems to be partly mediated by Th2 cells.

[1]  K. Okumura,et al.  The differential role of CD86 and CD80 co-stimulatory molecules in the induction and the effector phases of contact hypersensitivity. , 1996, International immunology.

[2]  G. Freeman,et al.  Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. , 1995, Transplantation.

[3]  M. Azuma,et al.  Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule , 1995, European journal of immunology.

[4]  G. Szot,et al.  Interleukin-12 inhibits murine graft-versus-host disease. , 1995, Blood.

[5]  W. Gause,et al.  Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. , 1995, Journal of immunology.

[6]  P. Linsley,et al.  Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. , 1995, Journal of immunology.

[7]  J. Bluestone.  New perspectives of C1328-137-mediated T cell costimulation , 1995 .

[8]  D. Loh,et al.  Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. , 1995, Journal of immunology.

[9]  B. Ryffel,et al.  The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon gamma in vivo , 1995, The Journal of experimental medicine.

[10]  S. Smith,et al.  Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. , 1995, Blood.

[11]  P. Linsley,et al.  CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. , 1994, Transplantation.

[12]  F. Finkelman,et al.  IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. , 1994, Journal of immunology.

[13]  P. Linsley,et al.  CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. , 1994, Transplantation.

[14]  G. Trinchieri,et al.  Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis. , 1994, Journal of immunology.

[15]  G. Trinchieri,et al.  B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation , 1994, The Journal of experimental medicine.

[16]  G. Trinchieri,et al.  Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells , 1994, The Journal of experimental medicine.

[17]  P. Linsley,et al.  In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. , 1994, Blood.

[18]  B. Hausmann,et al.  Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+ T cells and defective antibody production in vivo , 1994, The Journal of experimental medicine.

[19]  L. Lanier,et al.  B70 antigen is a second ligand for CTLA-4 and CD28 , 1993, Nature.

[20]  Kenneth M. Murphy,et al.  Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from αβ TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-γ production is IFN-γ-dependent , 1993 .

[21]  K P Lee,et al.  Differential T cell costimulatory requirements in CD28-deficient mice. , 1993, Science.

[22]  G. Trinchieri,et al.  Interleukin-12 and its role in the generation of TH1 cells. , 1993, Immunology today.

[23]  H. Weiner,et al.  Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. , 1993, Transplantation.

[24]  C. Sidman,et al.  Differential cytokine expression in acute and chronic murine graft‐versus‐host‐disease , 1993, European journal of immunology.

[25]  C Anasetti,et al.  Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1 , 1993, The Journal of experimental medicine.

[26]  R. Schwartz.  Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy , 1992, Cell.

[27]  P. Linsley,et al.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Linsley,et al.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. , 1992, Science.

[29]  M. Hallet,et al.  PERIPHERAL TOLERANCE OF AN ALLOGRAFT IN ADULT RATS—CHARACTERIZATION BY LOW INTERLEUKIN‐2 AND INTERFERON‐γ mRNA LEVELS AND BY STRONG ACCUMULATION OF MAJOR HISTOCOMPATIBILITY COMPLEX TRANSCRIPTS IN THE GRAFT , 1992, Transplantation.

[30]  L. Lanier,et al.  Multicolor immunofluorescence and flow cytometry , 1991 .

[31]  G. Trinchieri,et al.  Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers , 1991, The Journal of experimental medicine.

[32]  F. Hirayama,et al.  Synergistic interaction between interleukin-12 and steel factor in support of proliferation of murine lymphohematopoietic progenitors in culture. , 1994, Blood.

[33]  Methods : A Companion to Methods in Enzymology , 2022 .